^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

exicorilant (CORT125281)

i
Other names: CORT125281, CORT 125281
Associations
Trials
Company:
Corcept Therap
Drug class:
GCR antagonist, Cortisol modulator
Associations
Trials
1year
Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells. (PubMed, Cells)
GR silencing in DTX-sensitive and -resistant PCa cells decreased LEDGF/p75 expression, and GR upregulation in enzalutamide-resistant cells correlated with increased LEDGF/p75 expression...The GR modulators exicorilant and relacorilant increased the sensitivity of chemoresistant PCa cells to DTX-induced cell death, and this effect was more pronounced upon LEDGF/p75 silencing. RNA-sequencing of DTX-resistant cells with GR or LEDGF/p75 knockdown revealed a transcriptomic overlap targeting signaling pathways associated with cell survival and proliferation, cancer, and therapy resistance. These studies implicate the GR-LEDGF/p75 axis in PCa therapy resistance and provide a pre-clinical rationale for developing novel therapeutic strategies for advanced PCa.
Journal
|
PSIP1 (PC4 And SFRS1 Interacting Protein 1) • NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1)
|
PSIP1 expression
|
docetaxel • Xtandi (enzalutamide capsule) • relacorilant (CORT125134) • exicorilant (CORT125281)
over1year
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC (clinicaltrials.gov)
P1/2, N=39, Completed, Corcept Therapeutics | Active, not recruiting --> Completed
Trial completion
|
Xtandi (enzalutamide capsule) • abiraterone acetate • exicorilant (CORT125281)